Bristol Myers Squibb is buying Nvidia's latest AI computing system. This new system will support artificial intelligence in drug discovery and development. The company expects to cycle through many more potential drug candidates faster. AI tools are already cutting drug testing times by twenty to thirty percent. This investment drives rapidly growing computing demands across their research organization.

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

Bristol Myers Squibb is the third drugmaker in nine months to announce it is building the largest AI supercomputer in the life sciences industry.